Tecan Collaborates with Arizona State University to Rapidly Assess Radiation Exposure
News May 04, 2010
Tecan is collaborating with Arizona State University (ASU) to develop the Integrated Biodosimetry System, a prototype robotic system for high throughput screening to measure an individual’s level of exposure to radiation in the event of a radiological or nuclear incident.
The project, involving several prestigious organizations, is supported by the US Department of Health and Human Services’ Biomedical Advanced Research and Development Authority (BARDA), and focuses on development of a system to enable triage of patients than is currently possible. Tecan, the ASU Biodesign Institute and its partners hope to demonstrate proof-of-concept of the platform technology by the end of the current contract period.
Dr Carl Yamashiro, principal investigator at ASU’s Biodesign Institute, explained: “The research team will work with Tecan on building a comprehensive high throughput system, allowing scientists to analyze blood samples from up to 2,000 people per day, per instrument. The beauty of our system is its versatility. Not only will we be developing a system for the effective response to a nuclear or radiological event that could affect a large population, but the high throughout platform can also be used to advance genomics testing and other routine laboratory procedures that measure gene expression levels.”
Peter Siesel, Vice President of Sales and Marketing at Tecan, said: “We are pleased and excited to be part of this impressive collaboration. Tecan has a long history of providing world-class automation solutions for our partners and customers. This project is especially important because of its significance to the defense and protection of the US population.”
Researchers from the Spanish National Cancer Research Centre (CNIO) have shown in a new study that the gene therapy with telomerase that they have developed, and which has proven to be effective in mice against diseases caused by excessive telomere shortening and ageing, does not cause cancer or increase the risk of developing it, even in a cancer-prone setting.READ MORE
Scientists report a novel gene therapy that halts vision loss in a canine model of a blinding condition called autosomal dominant retinitis pigmentosa (adRP). The strategy could one day be used to slow or prevent vision loss in people with the disease. NEI is part of the National Institutes of Health.